This result suggests that the combination therapy not only expanded the entire polyclonal CD4+Foxp3- T-cell population in the metastatic tumor site and periphery, but also the subpopulation specific for the tumor antigen Twist. This evidence concerns the gene TWIST1 and neoplasm.